Transgene and Beckman Coulter sign companion diagnostic agreement
This article was originally published in Scrip
Transgene and Beckham Coulter have signed an agreement that will see the latter develop a companion diagnostic test to help select which patients will benefit from Transgene's TG4010, which is in development for treating advanced non small-cell lung cancer in combination with first line therapy.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.